|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 315.30 CHF | -0.76% |
|
+0.64% | +23.41% |
| 09/12 | Roche Says Lymphoma Treatment Lunsumio Might Be Effective Earlier | DJ |
| 09/12 | European Commission Approves Roche Lupus Nephritis Treatment | DJ |
| Capitalization | 27TCr 33TCr 29TCr 25TCr 46TCr 30,07000Cr 50TCr 3,12800Cr 1,21600Cr 14,25200Cr 1,25600Cr 1,22900Cr 52,51200Cr | P/E ratio 2025 * |
18.3x | P/E ratio 2026 * | 16.7x |
|---|---|---|---|---|---|
| Enterprise value | 28TCr 35TCr 30TCr 26TCr 49TCr 31,55100Cr 53TCr 3,28200Cr 1,27600Cr 14,95400Cr 1,31800Cr 1,29000Cr 55,09900Cr | EV / Sales 2025 * |
4.6x | EV / Sales 2026 * | 4.4x |
| Free-Float |
87.84% | Yield 2025 * |
3.13% | Yield 2026 * | 3.19% |
Last Transcript: Roche Holding AG
| 1 day | -0.76% | ||
| 1 week | +0.64% | ||
| Current month | +2.57% | ||
| 1 month | +17.47% | ||
| 3 months | +16.91% | ||
| 6 months | +17.56% | ||
| Current year | +23.41% |
| 1 week | 308.6 |  | 318.9 |
| 1 month | 280 | | 319 |
| Current year | 231.9 | | 319 |
| 1 year | 231.9 | | 319 |
| 3 years | 212.9 | | 319 |
| 5 years | 212.9 | | 404.2 |
| 10 years | 206.35 | | 404.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 15/03/2023 | |
Alan Hippe
DFI | Director of Finance/CFO | 58 | 06/06/2011 |
Wafaa Mamilli
CTO | Chief Tech/Sci/R&D Officer | 58 | 10/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
André Hoffmann
BRD | Director/Board Member | 67 | 01/01/1996 |
Severin Schwan
CHM | Chairman | 58 | 15/03/2023 |
| Director/Board Member | 72 | 03/03/2015 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 9.03% | 121 M€ | -.--% | - |
| 8.46% | 26 M€ | +11.31% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.76% | +0.64% | +22.59% | +3.51% | 34TCr | |
| -1.54% | -6.11% | +22.23% | +172.09% | 89TCr | |
| -0.82% | -2.66% | +33.66% | +13.78% | 49TCr | |
| -0.06% | -0.62% | +26.29% | +36.75% | 39TCr | |
| +0.10% | -1.51% | +27.00% | +19.71% | 28TCr | |
| +0.17% | +0.58% | +19.51% | +24.96% | 25TCr | |
| -2.06% | -4.10% | -6.65% | -10.93% | 25TCr | |
| +0.07% | -2.56% | -61.75% | -35.08% | 21TCr | |
| -2.30% | -7.24% | +13.05% | +12.63% | 17TCr | |
| -1.51% | -3.67% | +31.76% | +35.68% | 15TCr | |
| Average | -1.00% | -2.72% | +12.77% | +27.31% | 34.19TCr | |
| Weighted average by Cap. | -1.08% | -3.04% | +17.35% | +54.27% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 6.16TCr 7.64TCr 6.56TCr 5.74TCr 11TCr 6,86500Cr 11TCr 71TCr 28TCr 3,25400Cr 29TCr 28TCr 11,98800Cr | 6.31TCr 7.83TCr 6.73TCr 5.88TCr 11TCr 7,03800Cr 12TCr 73TCr 28TCr 3,33600Cr 29TCr 29TCr 12,29100Cr |
| Net income | 1.32TCr 1.64TCr 1.41TCr 1.23TCr 2.27TCr 1,47500Cr 2.47TCr 15TCr 5.96TCr 70TCr 6.16TCr 6.03TCr 2,57500Cr | 1.46TCr 1.82TCr 1.56TCr 1.36TCr 2.51TCr 1,63100Cr 2.73TCr 17TCr 6.6TCr 77TCr 6.81TCr 6.67TCr 2,84900Cr |
| Net Debt | 1.33TCr 1.65TCr 1.42TCr 1.24TCr 2.28TCr 1,48100Cr 2.48TCr 15TCr 5.99TCr 70TCr 6.19TCr 6.06TCr 2,58700Cr | 815.35Cr 1.01TCr 869.09Cr 759.74Cr 1.4TCr 91TCr 1.52TCr 9.46TCr 3.67TCr 43TCr 3.8TCr 3.72TCr 1,58700Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/25/09 | 315.30 CHF | -0.76% | 8,06,054 |
| 08/25/08 | 317.70 CHF | +2.19% | 10,32,888 |
| 05/25/05 | 310.90 CHF | +0.26% | 9,37,693 |
| 04/25/04 | 310.10 CHF | -1.18% | 10,18,755 |
| 03/25/03 | 313.80 CHF | +0.16% | 11,92,175 |
Delayed Quote Swiss Exchange, December 09, 2025 at 10:01 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROG Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition